Quarterly ResultMay 7, 2026, 09:31 AM
Harmony Biosciences Q1 Revenue $215.4M, Reaffirms $1B+ 2026 Guidance
AI Summary
Harmony Biosciences reported Q1 2026 net product revenue of $215.4 million, a 17% increase year-over-year, and reaffirmed its full-year 2026 net revenue guidance of over $1 billion. Despite strong demand for WAKIX, net income decreased by 29% to $32.5 million, or $0.55 per diluted share, primarily due to $32.0 million in upfront payments for new license agreements. The company is advancing its pipeline, protecting WAKIX IP, and focusing on business development, including new COO and CFO appointments.
Key Highlights
- Q1 2026 net product revenue grew 17% to $215.4 million from $184.7 million in Q1 2025.
- Reaffirmed 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
- Net income decreased 29% to $32.5 million, or $0.55 diluted EPS, due to $32.0 million in license payments.
- Filed patent infringement lawsuit against AET Pharma/Sandoz for amorphous pitolisant patent.
- Acquired exclusive license to a novel amorphous form of pitolisant with patent protection until 2042.
- Pitolisant GR NDA submission on track for Q2 2026, with anticipated PDUFA in Q1 2027.
- Phase 1 clinical PK data for Orexin-2 agonist BP-205 on track for mid-2026.
- Appointed Peter Anastasiou as COO and Glenn Reicin as CFO.
Price Impact
More from HRMY